{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:03:22Z","timestamp":1794265402735,"version":"4.9.0"},"reference-count":188,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC3404000"],"award-info":[{"award-number":["2023YFC3404000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82371781"],"award-info":[{"award-number":["82371781"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073752"],"award-info":[{"award-number":["82073752"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.biomaterials.2026.124210","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T07:31:35Z","timestamp":1775633495000},"page":"124210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["EGFR-targeted therapies based on antibody engineering and nanotechnology for colorectal cancer"],"prefix":"10.1016","volume":"333","author":[{"given":"Xingxing","family":"Shang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyang","family":"Nan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4305-9622","authenticated-orcid":false,"given":"Dianwen","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biomaterials.2026.124210_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"3","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.biomaterials.2026.124210_bib2","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.3390\/cancers17172810","article-title":"Advancements in targeted therapies for colorectal cancer: overcoming challenges and exploring future directions","volume":"17","author":"Khelwatty","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biomaterials.2026.124210_bib3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"1","author":"Cervantes","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biomaterials.2026.124210_bib4","doi-asserted-by":"crossref","first-page":"1340401","DOI":"10.3389\/fphar.2023.1340401","article-title":"Deciphering treatment resistance in metastatic colorectal cancer: roles of drug transports, EGFR mutations, and HGF\/c-MET signaling","author":"Albadari","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biomaterials.2026.124210_bib5","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41392-020-0116-z","article-title":"Comprehensive review of targeted therapy for colorectal cancer","volume":"1","author":"Xie","year":"2020","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.biomaterials.2026.124210_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175894","article-title":"A novel EGFR-specific recombinant ricin-panitumumab (scFv) immunotoxin against breast and colorectal cancer cell lines; in silico and in vitro analyses","author":"Naemi","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biomaterials.2026.124210_bib7","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.semcancer.2022.04.002","article-title":"EGFR signaling pathway as therapeutic target in human cancers","author":"Levantini","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.biomaterials.2026.124210_bib8","article-title":"Impact of EGFR expression on colorectal cancer patient prognosis and survival","author":"Jean\u2010Philippe","year":"2004","journal-title":"Ann. Oncol. : Off. J. Euro Soc. Med.Oncol."},{"key":"10.1016\/j.biomaterials.2026.124210_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1433033","article-title":"EGFR and MUC1 as dual-TAA drug targets for lung cancer and colorectal cancer","author":"Cui","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biomaterials.2026.124210_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1203296","article-title":"Case Report: longitudinal monitoring of clonal evolution by circulating tumor DNA for resistance to anti-EGFR antibody in a case of metastatic colorectal cancer","author":"Sagawa","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biomaterials.2026.124210_bib11","first-page":"572","article-title":"Overcoming the hurdles: surmounting acquired resistance to anti-EGFR therapy in metastatic colorectal cancer","volume":"11","author":"Sackstein","year":"2023","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"10.1016\/j.biomaterials.2026.124210_bib12","first-page":"9","article-title":"Efficacy and safety of Anti-EGFR therapy rechallenge in metastatic colorectal cancer: a systematic review and meta-analysis","volume":"1","author":"de Moraes","year":"2024","journal-title":"J. Gastrointest. Cancer"},{"key":"10.1016\/j.biomaterials.2026.124210_bib13","article-title":"Growth factors, PI3K\/AKT\/mTOR and MAPK signaling pathways in colorectal cancer pathogenesis: where are we now?","volume":"19","author":"Stefani","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biomaterials.2026.124210_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1398419","article-title":"Unveiling acquired resistance to anti-EGFR therapies in colorectal cancer: a long and winding road","author":"R\u00edos-Hoyo","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biomaterials.2026.124210_bib15","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s13046-022-02389-z","article-title":"Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer","volume":"1","author":"Yang","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.biomaterials.2026.124210_bib16","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s13046-021-02130-2","article-title":"Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies","volume":"1","author":"Zhou","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.biomaterials.2026.124210_bib17","article-title":"Targeting HER3 for cancer treatment: a new horizon for an old target","volume":"1","author":"Uliano","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.biomaterials.2026.124210_bib18","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1093\/oncolo\/oyad200","article-title":"Impact of Anti-EGFR therapies on HER2-Positive metastatic colorectal cancer: a systematic literature review and meta-analysis of clinical outcomes","volume":"10","author":"Bekaii-Saab","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.biomaterials.2026.124210_bib19","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1159\/000521845","article-title":"Next-Generation sequencing of circulating tumor DNA can optimize second-line treatment in RAS wild-type metastatic colorectal cancer after progression on anti-EGFR therapy: time to rethink our approach","volume":"4","author":"Mauri","year":"2022","journal-title":"Oncol. Res. Treat."},{"key":"10.1016\/j.biomaterials.2026.124210_bib20","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12929-025-01119-9","article-title":"EGF receptor in organ development, tissue homeostasis and regeneration","volume":"1","author":"Tito","year":"2025","journal-title":"J. Biomed. Sci."},{"issue":"A","key":"10.1016\/j.biomaterials.2026.124210_bib21","first-page":"3639","article-title":"Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition","volume":"5","author":"Yano","year":"2003","journal-title":"Anticancer Res."},{"key":"10.1016\/j.biomaterials.2026.124210_bib22","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.3390\/biom14091073","article-title":"Integrating computational design and experimental approaches for next-generation biologics","volume":"9","author":"Son","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.biomaterials.2026.124210_bib23","article-title":"EGFR-Based targeted therapy for colorectal cancer-promises and challenges","volume":"4","author":"Janani","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.biomaterials.2026.124210_bib24","article-title":"The application of inorganic nanoparticles in molecular targeted cancer therapy: EGFR targeting","author":"Sun","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biomaterials.2026.124210_bib25","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3390\/biom10030360","article-title":"Bispecific antibodies and antibody\u2013drug conjugates for cancer therapy: technological considerations","volume":"3","author":"Shim","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.biomaterials.2026.124210_bib26","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1039\/D0BM01904F","article-title":"Cetuximab functionalization strategy for combining active targeting and antimigration capacities of a hybrid composite nanoplatform applied to deliver 5-fluorouracil: toward colorectal cancer treatment","volume":"6","author":"Chen","year":"2021","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.biomaterials.2026.124210_bib27","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jconrel.2023.05.032","article-title":"Bispecific antibodies for targeted delivery of anti-cancer therapeutic agents: a review","author":"Beishenaliev","year":"2023","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.biomaterials.2026.124210_bib28","doi-asserted-by":"crossref","first-page":"6711","DOI":"10.1038\/s41467-021-26967-5","article-title":"ABHD5 inhibits YAP-induced c-Met overexpression and colon cancer cell stemness via suppressing YAP methylation","volume":"1","author":"Gu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biomaterials.2026.124210_bib29","first-page":"A1266","article-title":"1150 DM005, an EGFR \u00d7 MET bispecific antibody-drug conjugate, showed robust anti-tumor activity in PDX models","author":"Han","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biomaterials.2026.124210_bib30","doi-asserted-by":"crossref","first-page":"12894","DOI":"10.1038\/s41598-022-17210-2","article-title":"EGFR, HER2, and HER3 protein expression in paired primary tumor and lymph node metastasis of colorectal cancer","volume":"1","author":"Ye","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biomaterials.2026.124210_bib31","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41392-020-0204-0","article-title":"IGF-1R inhibition induces MEK phosphorylation to promote survival in colon carcinomas","volume":"1","author":"Wang","year":"2020","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.biomaterials.2026.124210_bib32","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/s41401-023-01221-4","article-title":"SIBP-03, a novel anti-HER3 antibody, exerts antitumor effects and synergizes with EGFR- and HER2-targeted drugs","volume":"4","author":"Li","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.biomaterials.2026.124210_bib33","doi-asserted-by":"crossref","first-page":"6169","DOI":"10.1021\/acs.molpharmaceut.3c00558","article-title":"Targeted hyperbranched nanoparticles for delivery of Doxorubicin in breast cancer brain metastasis","volume":"12","author":"Lim","year":"2023","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biomaterials.2026.124210_bib34","article-title":"Dual inhibition of EGFR and IGF-1R signaling leads to enhanced antitumor efficacy against esophageal squamous cancer","volume":"18","author":"Kang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biomaterials.2026.124210_bib35","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1038\/s41388-021-01863-w","article-title":"HGF\/c-MET pathway in cancer: from molecular characterization to clinical evidence","volume":"28","author":"Fu","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.biomaterials.2026.124210_bib36","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.3390\/cancers17101665","article-title":"Petosemtamab, a bispecific antibody targeting Epidermal Growth Factor Receptor (EGFR) and leucine-rich G repeat-containing protein-coupled receptor (LGR5) designed for broad clinical applications","volume":"10","author":"Lundberg","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"8_Supplement_1","key":"10.1016\/j.biomaterials.2026.124210_bib37","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1158\/1538-7445.AM2025-2883","article-title":"Abstract 2883: cetuximab increases LGR5 expression and enhances efficacy of LGR5 antibody-drug conjugates in patient-derived models of colorectal cancer","author":"High","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.biomaterials.2026.124210_bib38","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/bjc.2017.412","article-title":"LGR5 expression is regulated by EGF in early colorectal adenomas and governs EGFR inhibitor sensitivity","volume":"4","author":"Morgan","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biomaterials.2026.124210_bib39","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1158\/1078-0432.CCR-22-3713","article-title":"FDA approval summary: Amivantamab for the treatment of patients with non\u2013small cell lung cancer with EGFR Exon 20 insertion mutations","volume":"17","author":"Chon","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biomaterials.2026.124210_bib40","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1158\/0008-5472.CAN-15-2833","article-title":"A novel bispecific antibody targeting EGFR and cMet is effective against EGFR inhibitor-resistant lung tumors","volume":"13","author":"Moores","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.biomaterials.2026.124210_bib41","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1158\/1535-7163.MCT-20-0071","article-title":"Amivantamab (JNJ-61186372), an Fc enhanced EGFR\/cMet bispecific antibody, induces receptor downmodulation and antitumor activity by Monocyte\/Macrophage trogocytosis","volume":"10","author":"Vijayaraghavan","year":"2020","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.biomaterials.2026.124210_bib42","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2026.44.2_suppl.166","article-title":"Amivantamab plus FOLFOX or FOLFIRI in RAS\/BRAF wild-type metastatic colorectal cancer: Long-term follow-up from the phase 1b\/2 OrigAMI-1 study","author":"Chen","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biomaterials.2026.124210_bib43","first-page":"528","article-title":"Abstract 528: EMB-01: an innovative bispecific antibody targeting EGFR and cMet on tumor cells mediates a novel mechanism to improve anti-tumor efficacy","author":"Ren","year":"2020","journal-title":"Cancer Res. (Chicago, Ill.). 16_Supplement"},{"key":"10.1016\/j.biomaterials.2026.124210_bib44","doi-asserted-by":"crossref","first-page":"CT168","DOI":"10.1158\/1538-7445.AM2025-CT168","article-title":"Abstract CT168: EMB-01, an EGFR\/cMET bispecific antibody, in metastatic colorectal cancer: results from an international phase Ib\/II study","author":"Shen","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.biomaterials.2026.124210_bib45","article-title":"EMB-01, a tetravalent bispecific antibody, inducing Co-Degradation of EGFR and c-Met for enhanced anti-tumor efficacy","author":"Gao","year":"2025","journal-title":"Cancer Sci."},{"key":"10.1016\/j.biomaterials.2026.124210_bib46","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/d41573-020-00164-3","article-title":"Trispecific antibodies take to the clinic","volume":"10","author":"Mullard","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biomaterials.2026.124210_bib47","series-title":"Preliminary Dose Escalation Results from a first-in-human, Phase I\/II Study of GB263T, a Novel EGFR\/cMET\/cMET Trispecific Antibody, in Patients with Advanced EGFR-mutated (Egfrm) Non-small Cell Lung Cancer (NSCLC)","author":"Pavlakis","year":"2023"},{"key":"10.1016\/j.biomaterials.2026.124210_bib48","doi-asserted-by":"crossref","first-page":"LB538","DOI":"10.1158\/1538-7445.AM2022-LB538","article-title":"Abstract LB538: characterization of GB263T, a tri-specific antibody against EGFR\/cMET\/cMET for NSCLC","author":"Du","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.biomaterials.2026.124210_bib49","doi-asserted-by":"crossref","first-page":"4494","DOI":"10.1158\/1538-7445.AM2023-4494","article-title":"Abstract 4494: Multi-specific cMet x EGFR x VEGF antibody for difficult to treat cancers","author":"Chiu","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.biomaterials.2026.124210_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1533059","article-title":"A trispecific antibody targeting EGFR\/cMET\/VEGF-A demonstrates multiple mechanisms of action to inhibit wild-type and mutant NSCLC animal models","author":"Jin","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biomaterials.2026.124210_bib51","series-title":"First-Line anti-EGFR or anti-VEGF Therapy, Tumour Sidedness, and Survival: Results from the South Australian (SA) Metastatic Colorectal Cancer (mCRC) Registry","first-page":"42","author":"Krishnan","year":"2023"},{"key":"10.1016\/j.biomaterials.2026.124210_bib52","doi-asserted-by":"crossref","first-page":"6309","DOI":"10.1158\/1538-7445.AM2023-6309","article-title":"Abstract 6309: Anti-tumor efficacy of SI-B001, a novel EGFR \u00d7 HER3 bispecific antibody, against EGFR-driven epithelial tumors alone or in combination with paclitaxel and carboplatin","author":"Renshaw","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.biomaterials.2026.124210_bib53","first-page":"OF1","article-title":"Izalontamab (SI-B001), a novel EGFRxHER3 bispecific antibody in patients with locally advanced or metastatic epithelial tumor: results from first-in-human phase I\/Ib Study","author":"Xue","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biomaterials.2026.124210_bib54","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s43018-022-00359-0","article-title":"Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR \u00d7 LGR5 bispecific antibody with efficacy in epithelial tumors","volume":"4","author":"Herpers","year":"2022","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.biomaterials.2026.124210_bib55","doi-asserted-by":"crossref","first-page":"B042","DOI":"10.1158\/1535-7163.TARG-25-B042","article-title":"Abstract B042: preclinical evaluation of petosemtamab, an epidermal growth factor receptor (EGFR) and leucine-rich repeat-containing G protein-coupled receptor (LGR5) bispecific antibody, on cancer stem cells","author":"Slobodnyuk","year":"2025","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.biomaterials.2026.124210_bib56","doi-asserted-by":"crossref","first-page":"B033","DOI":"10.1158\/1535-7163.TARG-25-B033","article-title":"Abstract B033: Petosemtamab (MCLA-158) monotherapy or with chemotherapy in metastatic colorectal cancer: preliminary antitumor activity and safety data from a phase 2 trial","author":"Khushman","year":"2025","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.biomaterials.2026.124210_bib57","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1080\/19420862.2016.1160989","article-title":"XGFR, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer","volume":"4","author":"Schanzer","year":"2016","journal-title":"MABS-AUSTIN"},{"key":"10.1016\/j.biomaterials.2026.124210_bib58","doi-asserted-by":"crossref","first-page":"6364","DOI":"10.1158\/1538-7445.AM2024-6364","article-title":"Abstract 6364: the bispecific antibody KA-3006 against both EGFR and MET surpasses amivantamab in efficacy","author":"Wu","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.biomaterials.2026.124210_bib59","doi-asserted-by":"crossref","first-page":"S122","DOI":"10.1016\/S0959-8049(22)01124-8","article-title":"MCLA-129, a human anti-EGFR and anti-c-MET bispecific antibody, in patients with advanced NSCLC and other solid tumors: an ongoing phase 1\/2 study","author":"Ou","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.biomaterials.2026.124210_bib60","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.apsb.2024.01.009","article-title":"Bispecific antibody drug conjugates: making 1+1>2","volume":"5","author":"Gu","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.biomaterials.2026.124210_bib61","first-page":"E2987","article-title":"Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent","volume":"32","author":"Merchant","year":"2013","journal-title":"P Natl Acad. Sci.USA"},{"key":"10.1016\/j.biomaterials.2026.124210_bib62","doi-asserted-by":"crossref","first-page":"6059","DOI":"10.1158\/1078-0432.CCR-14-0543","article-title":"LY2875358, a neutralizing and internalizing Anti-MET bivalent antibody, inhibits HGF-Dependent and HGF-Independent MET activation and tumor growth","volume":"23","author":"Liu","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biomaterials.2026.124210_bib63","doi-asserted-by":"crossref","first-page":"25106","DOI":"10.1074\/jbc.M116.753491","article-title":"Balancing selectivity and efficacy of bispecific Epidermal Growth Factor Receptor (EGFR) \u00d7 c-MET antibodies and antibody-drug conjugates","volume":"48","author":"Sellmann","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biomaterials.2026.124210_bib64","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"8","author":"Labrijn","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biomaterials.2026.124210_bib65","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13045-017-0522-z","article-title":"Recent advances of bispecific antibodies in solid tumors","volume":"1","author":"Yu","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biomaterials.2026.124210_bib66","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1016\/j.apsb.2023.05.023","article-title":"Bispecific antibodies in cancer therapy: target selection and regulatory requirements","volume":"9","author":"Sun","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.biomaterials.2026.124210_bib67","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41571-024-00905-y","article-title":"Bispecific and multispecific antibodies in oncology: opportunities and challenges","volume":"7","author":"Goebeler","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biomaterials.2026.124210_bib68","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.csbj.2020.05.006","article-title":"Format and geometries matter: Structure-based design defines the functionality of bispecific antibodies","author":"Dickopf","year":"2020","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.biomaterials.2026.124210_bib69","doi-asserted-by":"crossref","first-page":"24689","DOI":"10.1074\/jbc.M115.651653","article-title":"Impact of cell-surface antigen expression on target engagement and function of an epidermal growth factor receptor \u00d7 c-MET bispecific antibody","volume":"41","author":"Jarantow","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biomaterials.2026.124210_bib70","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1158\/1538-7445.AM2016-873","article-title":"Abstract 873: a novel MET-EGFR bispecific antibody LY3164530 shows advantage over combining MET and EGFR antibodies in tumor inhibition and overcome resistance","author":"Liu","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.biomaterials.2026.124210_bib71","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00280-018-3623-7","article-title":"A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer","volume":"3","author":"Patnaik","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.biomaterials.2026.124210_bib72","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4161\/mabs.22854","article-title":"Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates","volume":"1","author":"Ritchie","year":"2013","journal-title":"MABS-AUSTIN."},{"key":"10.1016\/j.biomaterials.2026.124210_bib73","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1158\/1538-7445.AM2023-2978","article-title":"Abstract 2978: YH013, a novel EGFR x MET bispecific antibody-drug conjugate, exhibits potent antitumor efficacy","author":"Han","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.biomaterials.2026.124210_bib74","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody\u2013drug conjugates","volume":"3","author":"Tsuchikama","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biomaterials.2026.124210_bib75","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41587-019-0135-x","article-title":"A coiled-coil masking domain for selective activation of therapeutic antibodies","volume":"7","author":"Trang","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biomaterials.2026.124210_bib76","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1158\/1535-7163.MCT-15-0901","article-title":"ABT-414, an antibody\u2013drug conjugate targeting a tumor-selective EGFR epitope","volume":"4","author":"Phillips","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biomaterials.2026.124210_bib77","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s10637-020-00908-3","article-title":"A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR","volume":"5","author":"Cleary","year":"2020","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.biomaterials.2026.124210_bib78","doi-asserted-by":"crossref","first-page":"S810","DOI":"10.1016\/j.annonc.2024.08.1322","article-title":"1265P A promising MET-EGFR bispecific nanobody-drug conjugate therapy for multiple solid tumours","author":"Cai","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biomaterials.2026.124210_bib79","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1158\/1538-7445.AM2025-2961","article-title":"Abstract 2961: AZD9592, an EGFR\/cMET bispecific antibody-drug conjugate (ADC), demonstrates target-dependent efficacy in colorectal cancer (CRC) patient-derived xenograft (PDX) models","author":"Zheng","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.biomaterials.2026.124210_bib80","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1470-2045(24)00159-1","article-title":"BL-B01D1, a first-in-class EGFR\u2013HER3 bispecific antibody\u2013drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study","volume":"7","author":"Ma","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biomaterials.2026.124210_bib81","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1158\/1538-7445.AM2023-2642","article-title":"Abstract 2642: BL-B01D1, a novel EGFR\u00d7HER3-targeting ADC, demonstrates robust anti-tumor efficacy in preclinical evaluation","author":"Wan","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.biomaterials.2026.124210_bib82","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1001\/jamaoncol.2022.0503","article-title":"Evaluation of safety of treatment with anti-epidermal growth factor receptor antibody drug conjugate MRG003 in patients with advanced solid tumors: a phase 1 nonrandomized clinical trial: a Phase 1 nonrandomized Clinical Trial","volume":"7","author":"Qiu","year":"2022","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.biomaterials.2026.124210_bib83","first-page":"9007","article-title":"Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC)","author":"Janne","year":"2021","journal-title":"ASCO Meeting Abstracts"},{"key":"10.1016\/j.biomaterials.2026.124210_bib84","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1200\/JCO.23.00059","article-title":"First-in-Human, phase I dose-escalation and dose-expansion Study of trophoblast cell-surface antigen 2\u2013Directed antibody-drug Conjugate Datopotamab Deruxtecan in Non\u2013Small-Cell lung cancer: TROPION-PanTumor01","volume":"29","author":"Shimizu","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biomaterials.2026.124210_bib85","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1158\/1538-7445.AM2016-1217","article-title":"Abstract 1217: preclinical evaluation of a next-generation, EGFR targeting ADC that promotes regression in KRAS or BRAF mutant tumors","author":"Huang","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.biomaterials.2026.124210_bib86","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1158\/1538-7445.AM2017-50","article-title":"Abstract 50: HTI-1511, a novel anti-EGFR-ADC, overcomes mutation resistance and demonstrates significant activity against multiple tumor types in preclinical studies","author":"Bahn","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.biomaterials.2026.124210_bib87","article-title":"Regression of EGFR positive established solid tumors in mice with the conditionally active T cell engager TAK-186","volume":"6","author":"Dettling","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biomaterials.2026.124210_bib88","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","article-title":"Antibody\u2013drug conjugates for cancer","volume":"10200","author":"Chau","year":"2019","journal-title":"Lancet (N. Am. Ed.)"},{"key":"10.1016\/j.biomaterials.2026.124210_bib89","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-023-00783-w","article-title":"Optimizing the safety of antibody\u2013drug conjugates for patients with solid tumours","volume":"8","author":"Tarantino","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biomaterials.2026.124210_bib90","article-title":"Regulatory approval of photoimmunotherapy: photodynamic therapy that induces immunogenic cell death","volume":"1","author":"Gomes-da-Silva","year":"2020","journal-title":"OncoImmunology"},{"key":"10.1016\/j.biomaterials.2026.124210_bib91","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/cncr.34507","article-title":"Treatment\u2010related adverse events of antibody\u2013drug conjugates in clinical trials: a systematic review and meta\u2010analysis","volume":"2","author":"Zhu","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.biomaterials.2026.124210_bib92","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13045-022-01397-y","article-title":"Payload diversification: a key step in the development of antibody\u2013drug conjugates","volume":"1","author":"Conilh","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biomaterials.2026.124210_bib93","article-title":"Key considerations based on pharmacokinetic\/pharmacodynamic in the design of antibody-drug conjugates","author":"Gao","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biomaterials.2026.124210_bib94","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1021\/acs.bioconjchem.7b00062","article-title":"Effects of drug\u2013antibody ratio on pharmacokinetics, biodistribution, efficacy, and tolerability of antibody\u2013maytansinoid conjugates","volume":"5","author":"Sun","year":"2017","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.biomaterials.2026.124210_bib95","first-page":"448","article-title":"Monodisperse polysarcosine-based highly-loaded antibody-drug conjugates","volume":"14","author":"Viricel","year":"2019","journal-title":"Chem. Sci."},{"key":"10.1016\/j.biomaterials.2026.124210_bib96","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41523-023-00522-5","article-title":"Phase I study of A166, an antibody\u2012drug conjugate in advanced HER2-expressing solid tumours","volume":"1","author":"Zhang","year":"2023","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.biomaterials.2026.124210_bib97","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1158\/1078-0432.CCR-22-0456","article-title":"Phase I trial of a novel Anti-HER2 antibody\u2013drug conjugate, ARX788, for the treatment of HER2-Positive metastatic breast cancer","volume":"19","author":"Zhang","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biomaterials.2026.124210_bib98","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1158\/0008-5472.CAN-05-4489","article-title":"Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing","volume":"8","author":"Erickson","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.biomaterials.2026.124210_bib99","doi-asserted-by":"crossref","first-page":"9280","DOI":"10.1158\/0008-5472.CAN-08-1776","article-title":"Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate","volume":"22","author":"Lewis Phillips","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.biomaterials.2026.124210_bib100","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1039\/C8CS00676H","article-title":"Cleavable linkers in antibody-drug conjugates","volume":"16","author":"Bargh","year":"2019","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.biomaterials.2026.124210_bib101","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","article-title":"T-cell-engaging bispecific antibodies in cancer","volume":"10396","author":"van de Donk","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.biomaterials.2026.124210_bib102","article-title":"Progresses of T-cell-engaging bispecific antibodies in treatment of solid tumors","author":"Liu","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.biomaterials.2026.124210_bib103","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.1158\/0008-5472.CAN-21-2483","article-title":"A probody T cell-engaging bispecific antibody targeting EGFR and CD3 inhibits Colon cancer growth with limited toxicity","volume":"22","author":"Boustany","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.biomaterials.2026.124210_bib104","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/ijc.10557","article-title":"Extremely potent, rapid and costimulation\u2010independent cytotoxic T\u2010cell response against lymphoma cells catalyzed by a single\u2010chain bispecific antibody","volume":"6","author":"Dreier","year":"2002","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.biomaterials.2026.124210_bib105","doi-asserted-by":"crossref","first-page":"12605","DOI":"10.1073\/pnas.1000976107","article-title":"T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells","volume":"28","author":"Lutterbuese","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biomaterials.2026.124210_bib106","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.cell.2019.04.041","article-title":"Multifunctional natural killer cell engagers targeting NKp46 trigger protective tumor immunity","volume":"7","author":"Gauthier","year":"2019","journal-title":"CELL"},{"key":"10.1016\/j.biomaterials.2026.124210_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102991","article-title":"T-cell engager toxicity in clinical phase trials A systematic review and meta-analysis","author":"Za\u00efr","year":"2025","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.biomaterials.2026.124210_bib108","doi-asserted-by":"crossref","first-page":"12605","DOI":"10.1073\/pnas.1000976107","article-title":"T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells","volume":"28","author":"Lutterbuese","year":"2010","journal-title":"P Natl Acad. Sci.USA"},{"key":"10.1016\/j.biomaterials.2026.124210_bib109","article-title":"Bispecific T cell engager (BiTE) antibody constructs can mediate bystander tumor cell killing","volume":"8","author":"Ross","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.biomaterials.2026.124210_bib110","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1515\/hsz-2018-0451","article-title":"The multifaceted roles of tumor-associated proteases and harnessing their activity for prodrug activation","volume":"8","author":"Vasiljeva","year":"2019","journal-title":"Biol. Chem."},{"key":"10.1016\/j.biomaterials.2026.124210_bib111","doi-asserted-by":"crossref","first-page":"A164","DOI":"10.1158\/1535-7163.TARG-17-A164","article-title":"Abstract A164: EGFR-CD3 bispecific probody\u2122 therapeutic induces tumor regressions and increases maximum tolerated dose >60-fold in preclinical studies","author":"Boustany","year":"2018","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.biomaterials.2026.124210_bib112","doi-asserted-by":"crossref","first-page":"A203","DOI":"10.1158\/1535-7163.TARG-15-A203","article-title":"Abstract A203: CD3-EGFR bispecific probody\u2122 therapeutics induced tumor regressions and increased therapeutic window in preclinical studies","author":"LaPorte","year":"2015","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.biomaterials.2026.124210_bib113","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s43018-023-00536-9","article-title":"Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors","volume":"4","author":"Cattaruzza","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.biomaterials.2026.124210_bib114","article-title":"Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer","volume":"1","author":"Tapia-Galisteo","year":"2022","journal-title":"OncoImmunology"},{"key":"10.1016\/j.biomaterials.2026.124210_bib115","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1051875","article-title":"TriTECM: a tetrafunctional T-cell engaging antibody with built-in risk mitigation of cytokine release syndrome","author":"Carrara","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biomaterials.2026.124210_bib116","article-title":"BiTE (CD3\u00d7EGFR)-Based triplet therapy unlocks CD40\/CD40L Crosstalk to revert immunosuppression in third-generation EGFR-TKI-Refractory NSCLC","author":"Guo","year":"2026","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.biomaterials.2026.124210_bib117","author":"Lin","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biomaterials.2026.124210_bib118","doi-asserted-by":"crossref","first-page":"B04","DOI":"10.1158\/2326-6074.TUMIMM22-B04","article-title":"Abstract B04: preclinical activity and safety profile or JANX008, a novel EGFR-targeting tumor-activated T cell engager for treatment of solid tumors","author":"DiRaimondo","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.biomaterials.2026.124210_bib119","series-title":"Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study","year":"2025"},{"key":"10.1016\/j.biomaterials.2026.124210_bib120","doi-asserted-by":"crossref","first-page":"7320","DOI":"10.1158\/1538-7445.AM2025-7320","article-title":"Abstract 7320: KGX105, a conditionally active prodrug of EGFRxCD3 T cell engager induces anti-tumor potency","author":"Gao","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.biomaterials.2026.124210_bib121","article-title":"Heterogeneous and evolving epitope landscape of clinical anti-drug antibodies against multidomain biotherapeutic: a case study of TAK-186","volume":"1","author":"Sun","year":"2025","journal-title":"mAbs"},{"key":"10.1016\/j.biomaterials.2026.124210_bib122","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1182\/blood.2022016243","article-title":"A novel CD19\/CD22\/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL","volume":"16","author":"Zhao","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.biomaterials.2026.124210_bib123","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ccell.2017.02.001","article-title":"Membrane-Proximal epitope facilitates efficient T cell synapse Formation by Anti-FcRH5\/CD3 and is a requirement for myeloma cell killing","volume":"3","author":"Li","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biomaterials.2026.124210_bib124","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1158\/1538-7445.AM2020-4555","article-title":"Abstract 4555: selection of CD3 affinity allows generation of T-cell redirecting bispecific antibodies with unique pharmacokinetic and biodistribution properties","author":"Haber","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.biomaterials.2026.124210_bib125","article-title":"Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release","volume":"6","author":"Dang","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biomaterials.2026.124210_bib126","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1158\/2326-6066.CIR-14-0161","article-title":"The immunological synapse","volume":"11","author":"Dustin","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.biomaterials.2026.124210_bib127","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13045-023-01482-w","article-title":"Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies","volume":"1","author":"Tapia-Galisteo","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biomaterials.2026.124210_bib128","first-page":"325","article-title":"Sparing of first dose effect of monovalent anti-CD3 antibody used in allograft rejection is associated with diminished release of pro-inflammatory cytokines","volume":"6","author":"Abbs","year":"1994","journal-title":"Ther. Immunol."},{"key":"10.1016\/j.biomaterials.2026.124210_bib129","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s00018-014-1751-8","article-title":"New prodrug form of Affibody molecules (pro-Affibody) is selectively activated by cancer-associated proteases","volume":"7","author":"Sandersj\u00f6\u00f6","year":"2015","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.biomaterials.2026.124210_bib130","doi-asserted-by":"crossref","first-page":"102975","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK cells: a promising cellular immunotherapy for cancer","author":"Xie","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.biomaterials.2026.124210_bib131","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1002\/eji.202048953","article-title":"Natural killer cell engagers in cancer immunotherapy: next generation of immuno\u2010oncology treatments","volume":"8","author":"Demaria","year":"2021","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.biomaterials.2026.124210_bib132","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s40164-024-00561-z","article-title":"Natural killer cell-based cancer immunotherapy: from basics to clinical trials","volume":"1","author":"Shi","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.biomaterials.2026.124210_bib133","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/ni1582","article-title":"Functions of natural killer cells","volume":"5","author":"Vivier","year":"2008","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.biomaterials.2026.124210_bib134","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.e14001","article-title":"EGFR\/CD16A tetravalent bispecific antibody AFM24 to engage NK-cells to kill EGFR expressing tumor cells and safety results in cynomolgus monkey studies","author":"Kerber","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biomaterials.2026.124210_bib135","first-page":"TPS2673","article-title":"AFM24 in combination with atezolizumab in patients with advanced EGFR-expressing solid tumors: phase 1\/2a study design and rationale","author":"Saavedra Santa Gadea","year":"2022","journal-title":"ASCO Meeting Abstracts"},{"key":"10.1016\/j.biomaterials.2026.124210_bib136","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1158\/1078-0432.CCR-24-1991","article-title":"First-in-Human phase I Study of a CD16A bispecific innate cell engager, AFM24, targeting EGFR-Expressing solid tumors","volume":"7","author":"El-Khoueiry","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biomaterials.2026.124210_bib137","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1158\/1538-7445.AM2021-1881","article-title":"Abstract 1881: AFM24 is a novel, highly potent, tetravalent bispecific EGFR\/CD16A-targeting Innate Cell Engager (ICE\u00ae) designed for the treatment of EGFR-positive malignancies","author":"Pahl","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.biomaterials.2026.124210_bib138","doi-asserted-by":"crossref","first-page":"5659","DOI":"10.1158\/1538-7445.AM2020-5659","article-title":"Abstract 5659: AFM24, a bispecific EGFR\/CD16A innate cell engager with the potential to overcome resistance to current targeted treatments for EGFR-positive malignancies","author":"Reusch","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.biomaterials.2026.124210_bib139","article-title":"Investigating the novel CD16A and epidermal growth factor receptor (EGFR) bispecific innate cell engager, AFM24, to leverage the innate immune system: interim results from the colorectal cancer (CRC) cohort","author":"Rivas","year":"2023","journal-title":"ASCO Meeting Abstracts"},{"key":"10.1016\/j.biomaterials.2026.124210_bib140","doi-asserted-by":"crossref","unstructured":"M. Bigelow, C. LaCroix, M.K. Chawla, Z. Fagiani, S. Basinski, P. Kirby, S. Hicks, S. Juo, A. Grinberg, N. Wagtmann, 1060 DF9001, an EGFR targeted immune engager, stimulates innate and adaptive anti-tumor immunity with a distinctive safety profile, BMJ Specialist J. 12 (2024) A1180. dio: 10.1136\/jitc-2024-sitc2024.1060.","DOI":"10.1136\/jitc-2024-SITC2024.1060"},{"key":"10.1016\/j.biomaterials.2026.124210_bib141","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1158\/1538-7445.AM2024-1341","article-title":"Abstract 1341: SM2235: a bispecific EGFR x CD16A innate immune cell engager for enhanced treatment of EGFR-expressing solid tumors, regardless of RAS mutation status","author":"Geng","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.biomaterials.2026.124210_bib142","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41586-023-06945-1","article-title":"Natural killer cell therapies","volume":"8000","author":"Vivier","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.biomaterials.2026.124210_bib143","article-title":"Nanoscale restructuring of the immune synapse with an engager enhances NK cell function","volume":"38","author":"Hazime","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biomaterials.2026.124210_bib144","article-title":"Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy","volume":"27","author":"Au","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.biomaterials.2026.124210_bib145","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.3390\/vaccines10071033","article-title":"NK cell-based immunotherapy in colorectal cancer","volume":"7","author":"Della Chiesa","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.biomaterials.2026.124210_bib146","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1177\/1753425912453187","article-title":"Altered phenotype in peripheral blood and tumor-associated NK cells from colorectal cancer patients","volume":"1","author":"Rocca","year":"2013","journal-title":"Innate. Immun.-London"},{"key":"10.1016\/j.biomaterials.2026.124210_bib147","first-page":"S2747","article-title":"Early intervention in cancer using monoclonal antibodies and other biological ligands: micropharmacology and the \"binding site barrier\"","volume":"9","author":"Weinstein","year":"1992","journal-title":"Cancer Res."},{"key":"10.1016\/j.biomaterials.2026.124210_bib148","article-title":"Antibody\u2010Nanoparticle conjugates in therapy: combining the best of two worlds","volume":"15","author":"Adhikari","year":"2025","journal-title":"Small"},{"key":"10.1016\/j.biomaterials.2026.124210_bib149","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3390\/molecules26030567","article-title":"Effect of cetuximab-conjugated gold nanoparticles on the cytotoxicity and phenotypic evolution of colorectal cancer cells","volume":"3","author":"El Hallal","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.biomaterials.2026.124210_bib150","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2217\/nnm-2022-0240","article-title":"Targeted delivery of panitumumab-scaffold bosutinib-encapsulated polycaprolactone nanoparticles for EGFR-overexpressed colorectal cancer","volume":"9","author":"Bhattacharya","year":"2023","journal-title":"Nanomedicine (Lond)."},{"key":"10.1016\/j.biomaterials.2026.124210_bib151","article-title":"pH-responsive and CD44-targeting polymer micelles based on CD44p-conjugated amphiphilic block copolymer PEG-b-HES-b-PLA for delivery of emodin to breast cancer cells","volume":"27","author":"Cheng","year":"2022","journal-title":"Nano"},{"key":"10.1016\/j.biomaterials.2026.124210_bib152","doi-asserted-by":"crossref","DOI":"10.1016\/j.chemphyslip.2023.105280","article-title":"EGFR-targeted hybrid lipid nanoparticles for chemo-photothermal therapy against colorectal cancer cells","author":"Fang","year":"2023","journal-title":"Chem. Phys. Lipids"},{"key":"10.1016\/j.biomaterials.2026.124210_bib153","doi-asserted-by":"crossref","first-page":"122349","DOI":"10.1016\/j.biomaterials.2023.122349","article-title":"A LIGHTFUL nanomedicine overcomes EGFR-mediated drug resistance for enhanced tyrosine-kinase-inhibitor-based hepatocellular carcinoma therapy","author":"Yi","year":"2023","journal-title":"Biomaterials"},{"key":"10.1016\/j.biomaterials.2026.124210_bib154","article-title":"Antibody\u2010Incorporated nanomedicines for cancer therapy","volume":"24","author":"Wu","year":"2022","journal-title":"Adv. Mater."},{"key":"10.1016\/j.biomaterials.2026.124210_bib155","doi-asserted-by":"crossref","first-page":"118","DOI":"10.7150\/thno.13069","article-title":"Bispecific antibody conjugated manganese-based magnetic engineered iron oxide for imaging of HER2\/neu-and EGFR-expressing tumors","volume":"1","author":"Wu","year":"2016","journal-title":"Theranostics"},{"key":"10.1016\/j.biomaterials.2026.124210_bib156","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41392-023-01642-x","article-title":"Smart nanoparticles for cancer therapy","volume":"1","author":"Sun","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.biomaterials.2026.124210_bib157","doi-asserted-by":"crossref","first-page":"29265","DOI":"10.1038\/s41598-024-80879-0","article-title":"EGFR-targeting polydopamine nanoparticles co-loaded with 5-fluorouracil, irinotecan, and leucovorin to potentially enhance metastatic colorectal cancer therapy","volume":"1","author":"Djermane","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biomaterials.2026.124210_bib158","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1021\/mp400212v","article-title":"Inhibition of tumor growth by targeted Anti-EGFR\/IGF-1R nanobullets depends on efficient blocking of cell survival pathways","volume":"10","author":"van der Meel","year":"2013","journal-title":"Mol. Pharmaceut."},{"key":"10.1016\/j.biomaterials.2026.124210_bib159","doi-asserted-by":"crossref","first-page":"5984","DOI":"10.1021\/acsami.4c18748","article-title":"NIR II laser-triggered photothermal nanoplatform for multimodal imaging-guided synergistic therapy toward Colon cancer","volume":"4","author":"Ren","year":"2025","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.biomaterials.2026.124210_bib160","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.2147\/IJN.S289228","article-title":"Egfr targeted cetuximab-valine-citrulline (Vc)-doxorubicin immunoconjugates-loaded bovine serum albumin (bsa) nanoparticles for colorectal tumor therapy","author":"Ye","year":"2021","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.biomaterials.2026.124210_bib161","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jconrel.2017.04.031","article-title":"EGFR-targeted micelles containing near-infrared dye for enhanced photothermal therapy in colorectal cancer","author":"Shih","year":"2017","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.biomaterials.2026.124210_bib162","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jconrel.2020.01.035","article-title":"Functionalizing nanoparticles with cancer-targeting antibodies: a comparison of strategies","author":"Marques","year":"2020","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.biomaterials.2026.124210_bib163","article-title":"One-step mixing with humanized anti-mPEG bispecific antibody enhances tumor accumulation and therapeutic efficacy of mPEGylated nanoparticles","author":"Chien-Han","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.biomaterials.2026.124210_bib164","article-title":"Recent advances in the generation of antibody\u2013nanomaterial conjugates","volume":"1","author":"Sivaram","year":"2018","journal-title":"Adv. Healthc Mater."},{"key":"10.1016\/j.biomaterials.2026.124210_bib165","article-title":"Strategies for non-covalent attachment of antibodies to PEGylated nanoparticles for targeted drug delivery","author":"Kai\u2010Wen","year":"2024","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.biomaterials.2026.124210_bib166","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s12943-025-02501-9","article-title":"Bispecific antibodies and nanotechnology: a strategic alliance in cancer immunotherapy","volume":"1","author":"Battistini","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biomaterials.2026.124210_bib167","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/j.addr.2013.09.019","article-title":"Nanomedicine therapeutic approaches to overcome cancer drug resistance","volume":"13\u201314","author":"Markman","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biomaterials.2026.124210_bib168","article-title":"Site\u2010Specific antibody assembly on nanoparticles via a versatile coating method for improved cell targeting","volume":"9","author":"Zhang","year":"2023","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.biomaterials.2026.124210_bib169","article-title":"Nanobody-based drug delivery systems for cancer therapy","author":"Liu","year":"2025","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.biomaterials.2026.124210_bib170","article-title":"Targeted mRNA delivery with bispecific antibodies that tether LNPs to cell-surface markers","author":"Bettina","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.biomaterials.2026.124210_bib171","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.3390\/ijms21176018","article-title":"Antibody conjugation of nanoparticles as therapeutics for breast cancer treatment","volume":"17","author":"Juan","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biomaterials.2026.124210_bib172","article-title":"Dual ligand immunoliposomes for drug delivery to the brain","author":"Joana","year":"2015","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.biomaterials.2026.124210_bib173","article-title":"Modulating targeting of poly(ethylene glycol) particles to tumor cells using bispecific antibodies","volume":"9","author":"Cui","year":"2019","journal-title":"Adv. Healthc Mater."},{"key":"10.1016\/j.biomaterials.2026.124210_bib174","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1021\/acs.accounts.3c00172","article-title":"Functional ligand-enabled particle assembly for Bio\u2013Nano interactions","volume":"13","author":"Ju","year":"2023","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.biomaterials.2026.124210_bib175","doi-asserted-by":"crossref","first-page":"6094","DOI":"10.1039\/C5TB00790A","article-title":"The control of epidermal growth factor grafted on mesoporous silica nanoparticles for targeted delivery","volume":"29","author":"She","year":"2015","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.biomaterials.2026.124210_bib176","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1021\/acsnano.1c08277","article-title":"A single-molecule view at nanoparticle targeting selectivity: correlating ligand functionality and cell receptor density","volume":"3","author":"Woythe","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.biomaterials.2026.124210_bib177","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41577-024-01111-8","article-title":"Cancer immune evasion, immunoediting and intratumour heterogeneity","volume":"5","author":"Roerden","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biomaterials.2026.124210_bib178","article-title":"Conjugation chemistry markedly impacts toxicity and biodistribution of targeted nanoparticles, mediated by complement activation","volume":"5","author":"Zaleski","year":"2025","journal-title":"Adv. Mater."},{"key":"10.1016\/j.biomaterials.2026.124210_bib179","series-title":"Galloylated Liposomes Enable Targeted Drug Delivery by Overcoming Protein Corona Shielding","author":"Wang","year":"2025"},{"key":"10.1016\/j.biomaterials.2026.124210_bib180","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"14","author":"Van Cutsem","year":"2009","journal-title":"NEW ENGL. J.MED."},{"key":"10.1016\/j.biomaterials.2026.124210_bib181","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1200\/JCO.22.02758","article-title":"Wild-Type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer","volume":"18","author":"Amado","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biomaterials.2026.124210_bib182","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.TARG-19-LB-C07","article-title":"Abstract LB-C07: preclinical evaluation of MCLA-129: a bispecific antibody targeting c-MET and EGFR","author":"Geuijen","year":"2019","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.biomaterials.2026.124210_bib183","doi-asserted-by":"crossref","first-page":"6580","DOI":"10.1158\/1538-7445.AM2024-6580","article-title":"Abstract 6580: a Novel EGFR x cMET bispecific ADC PRO1286 demonstrated broad antitumor activity and promising tolerability in preclinical models","author":"Xiao","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.biomaterials.2026.124210_bib184","doi-asserted-by":"crossref","first-page":"LB043","DOI":"10.1158\/1538-7445.AM2024-LB043","article-title":"Abstract LB043: VBC101-F11: an innovative EGFR\/cMet bispecific antibody drug conjugate (ADC) targeting key oncogenic drivers in solid tumors","author":"Wang","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.biomaterials.2026.124210_bib185","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1158\/1538-7445.AM2025-2965","article-title":"Abstract 2965: SCR-A006, an innovative and potential best-in-class EGFR\/cMet bispecific antibody-drug conjugate","author":"Fu","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.biomaterials.2026.124210_bib186","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1158\/1538-7445.AM2024-2619","article-title":"Abstract 2619: a novel EGFR \u00d7 HER3-targeting bispecific antibody drug-conjugate, BCG019, demonstrates robust anti-tumor efficacy in preclinical evaluation","author":"Li","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.biomaterials.2026.124210_bib187","article-title":"EGFR-targeted micelles containing near-infrared dye for enhanced photothermal therapy in colorectal cancer","author":"Ying\u2010Hsia","year":"2017","journal-title":"J. Contr. Release : Off. . Controlled Release Soc."},{"key":"10.1016\/j.biomaterials.2026.124210_bib188","doi-asserted-by":"crossref","first-page":"9689","DOI":"10.2147\/IJN.S473473","article-title":"EGFR-Targeted and NIR-Triggered lipid-polymer hybrid nanoparticles for chemo-photothermal colorectal tumor therapy","author":"Fang","year":"2024","journal-title":"Int. J. Nanomed."}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961226002346?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961226002346?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:32:12Z","timestamp":1793946732000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961226002346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":188,"alternative-id":["S0142961226002346"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2026.124210","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EGFR-targeted therapies based on antibody engineering and nanotechnology for colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2026.124210","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"124210"}}